https://doi.org/
Poster
NOT PEER REVIEWED
Download
metrics
VIEWS
196
 
downloads
30
CITE
How to cite this poster:
Licht C, Muus P, Legendre C et al. Eculizumab (ECU) safety and efficacy in atypical hemolytic uremic syndrome (aHUS) patients with long disease duration and chronic kidney disease (CKD): 2-year results. F1000Posters 2015, 6:59 (poster)

Eculizumab (ECU) safety and efficacy in atypical hemolytic uremic syndrome (aHUS) patients with long disease duration and chronic kidney disease (CKD): 2-year results

Christoph Licht1, Petra Muus, Christophe Legendre, Kenneth Douglas, Maryvonne Hourmant, Yahsou Delmas, Maria Herthelius, Antonella Trivelli, Timothy Goodship, Camille Bedrosian, Chantal Loirat
Published 19 Jan 2015
Author Affiliations
  • Metrics
  • 196 Views
  • 30 Downloads
Browse by related subjects
Published 19 Jan 2015

Eculizumab (ECU) safety and efficacy in atypical hemolytic uremic syndrome (aHUS) patients with long disease duration and chronic kidney disease (CKD): 2-year results

[version 1; not peer reviewed]

Christoph Licht1, Petra Muus, Christophe Legendre, Kenneth Douglas, Maryvonne Hourmant, Yahsou Delmas, Maria Herthelius, Antonella Trivelli, Timothy Goodship, Camille Bedrosian, Chantal Loirat
Author Affiliations
1 The Hospital for Sick Children, Canada
Presented at
54th American Society of Hematology Annual Meeting 2012
Abstract
Competing Interests

Dr. Licht has received fees for consultancy, research funding, and honoraria from Alexion Pharmaceuticals. Dr. Muus has been a member of an advisory board for Alexion Pharmaceuticals. Dr. Legendre has received compensation for participation in a speakers’ bureau for Alexion Pharmaceuticals. Dr. Goodship has received research funding, honoraria, and compensation for participation in a speakers’ bureau from Alexion Pharmaceuticals and has been a member of an advisory board for Alexion Pharmaceuticals. Dr. Bedrosian is an employee of Alexion Pharmaceuticals. Dr. Loirat has been a coordinator of eculizumab trials for, and received honoraria for conferences from, Alexion Pharmaceuticals. Drs. Douglas, Hourmant, Delmas, Herthelius, and Trivelli have no financial relationships to disclose. This study was sponsored by Alexion Pharmaceuticals, Inc.

Comments
0 Comments
 
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.